Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Current Deferred Revenue (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Current Deferred Revenue for 2 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 28.7% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, up 28.7%, while the annual FY2025 figure was $2.0 million, 28.7% up from the prior year.
  • Current Deferred Revenue was $2.0 million for Q4 2025 at Day One Biopharmaceuticals, down from $2.3 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $2.3 million in Q3 2025, with the low at $1.5 million in Q3 2024.